F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists

European Neuropsychopharmacology

Volumn 20, Issue 9, 2010, Pages 641-654

  Depoortère, Ronan ^a   Auclair, Agnès L ^a   Bardin, Laurent ^a   Colpaert, Francis C ^a   Vacher, Bernard ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Cognition; Memory; Post synaptic receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 CHLORO 4 FLUOROPHENYL [4 FLUORO 4 [[(5 METHYL 6 METHYLAMINOPYRIDIN 2 YLMETHYL)AMINO]METHYL]PIPERIDIN 1 YL]METHANONE; 3 CHLORO 4 FLUOROPHENYL [4 FLUORO 4 [[(5 METHYLPYRIMIDIN 2 YLMETHYL)AMINO]METHYL]PIPERIDIN 1 YL]METHANONE; F 13714; F 15599; PHENCYCLIDINE; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; LEARNING; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; REFERENCE MEMORY; SEROTONINERGIC SYSTEM; STARTLE REFLEX; WORKING MEMORY;

EID: 77954102626     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.04.005     Document Type: Article

References (49)

1. Assié M.B., Ravailhe V., Faucillon V., Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther. 2005, 315:265-272.
2. 1A receptor agonist: in vivo profile in neurochemical and behavioural models of serotonergic activity. Eur. Neuropsychopharmacol. 2006, 16:S233.
3. 1A receptor agonist: in vivo profile in behavioural models of antidepressant and serotonergic activity. Int. J. Neuropsychopharm. 2010, 11:1-14.
4. Auclair A.L., Kleven M.S., Besnard J., Depoortere R., Newman-Tancredi A. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology 2006, 31:1900-1909.
5. Auclair A.L., Galinier A., Besnard J., Newman-Tancredi A., Depoortere R. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats. Psychopharmacology (Berl) 2007, 193:45-54.
6. Auclair A.L., Besnard J., Newman-Tancredi A., Depoortere R. The five choice serial reaction time task: comparison between Sprague-Dawley and Long-Evans rats on acquisition of task, and sensitivity to phencyclidine. Pharmacol. Biochem. Behav. 2009, 92:363-369.
7. Beck L.H., Bransome E.D., Mirsky A.F., Rosvold H.E., Sarason I. A continuous performance test of brain damage. J. Consult. Psychol. 1956, 20:343-350.
8. Bouger P.C., van der Staay F.J. Rats with scopolamine- or MK-801-induced spatial discrimination deficits in the cone field task: animal models for impaired spatial orientation performance. Eur. Neuropsychopharmacol. 2005, 15:331-346.
9. Carli M., Robbins T.W., Evenden J.L., Everitt B.J. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav. Brain Res. 1983, 9:361-380.
10. Celada P., Llado L., Assié M.-B., Newman-Tancredi A., Artigas F. F15599, a 5-HT1A agonist that preferentially targets post-synaptic receptors in the frontal cortex: IV) Influence on rat raphe and pyramidal neuronal activity and cortical dopamine release. 37th Annual Meeting of the Society for Neuroscience; Nov 3-7; San Diego, 170.27 2007.
11. Cole B.J., Klewer M., Jones G.H., Stephens D.N. Contrasting effects of the competitive NMDA antagonist CPP and the non-competitive NMDA antagonist MK 801 on performance of an operant delayed matching to position task in rats. Psychopharmacology (Berl) 1993, 111:465-471.
12. Depoortere R., Auclair A.L., Bardin L., Bruins S.L., Kleven M.S., Colpaert F., Vacher B., Newman-Tancredi A. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. Br. J. Pharmacol. 2007, 151:266-277.
13. Diaz-Mataix L., Scorza M.C., Bortolozzi A., Toth M., Celada P., Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 2005, 25:10831-10843.
14. Geyer M.A., Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1071-1079.
15. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
16. Hall M.D., Gozlan H., Emerit M.B., El Mestikawy S., Pichat L., Hamon M. Differentiation of pre- and post-synaptic high affinity serotonin receptor binding sites using physico-chemical parameters and modifying agents. Neurochem. Res. 1986, 11:891-912.
17. Ichikawa J., Meltzer H.Y. The effect of serotonin1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 2000, 858:252-263.
18. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148:1301-1308.
19. Jones G.H., Marsden C.A., Robbins T.W. Behavioural rigidity and rule-learning deficits following isolation-rearing in the rat: neurochemical correlates. Behav. Brain Res. 1991, 43:35-50.
20. Kleven M.S., Assié M.B., Koek W. Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J. Pharmacol. Exp. Ther. 1997, 282:747-759.
21. Koek W., Vacher B., Cosi C., Assie M.B., Patoiseau J.F., Pauwels P.J., Colpaert F.C. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur. J. Pharmacol. 2001, 420:103-112.
22. Lemoine L., Verdurand M., Vacher B., Blanc E., Le Bars D., Newman-Tancredi A., Zimmer L. [(18)F]F15599, a novel 5-HT(1A) receptor agonist, as a radioligand for PET neuroimaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:594-605.
23. Leonard J.A. 5 choice serial reaction apparatus. Anonymous, Med. Res. Council Appl. Psychol. Res. Unit Rep., Great Britain 1959.
24. Lieben C.K., van Oorsouw K., Deutz N.E., Blokland A. Acute tryptophan depletion induced by a gelatin-based mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav. Brain Res. 2004, 151:53-64.
25. Light G.A., Braff D.L., Sprock J., Cadenhead K.S., Swerdlow N.R. Prepulse inhibition of startle is positively associated with higher order cognition in women. 37th Annual Meeting of the Society for Neuroscience; Nov 3-7; San Diego, 806.17/W7 2007.
26. Llado-Pelfort, L., Assié, M.-B., Newman-Tancredi, A., Celada, P., Artigas, F. , in press. Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors. B. J. Pharmacol. doi:10.1111/j.1476-5381.2010.00738.x.
27. Mannoury la Cour C., El Mestikawy S., Hanoun N., Hamon M., Lanfumey L. Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Mol. Pharmacol. 2006, 70:1013-1021.
28. Mauler F., Fahrig T., Horvath E., Jork R. Inhibition of evoked glutamate release by the neuroprotective 5-HT(1A) receptor agonist BAY x 3702 in vitro and in vivo. Brain Res. 2001, 888:150-157.
29. Maurel J.L., Autin J.M., Funes P., Newman-Tancredi A., Colpaert F., Vacher B. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. J. Med. Chem. 2007, 50:5024-5033.
30. Meltzer H.Y., Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav. Brain Res. 2008, 195:98-102.
31. Meneses A., Perez-Garcia G. 5-HT(1A) receptors and memory. Neurosci. Biobehav. Rev. 2007, 31:705-727.
32. Mirski A.F., Rosvold H.E. The use of psychoactive drugs as a neuropsychological tool in studies of attention in man. Drugs and Behavior, Vol. 1960, 375-392. Wiley, New York. I. Uhr, J.G. Miller (Eds.).
33. Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 2004, 174:39-44.
34. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
35. Nanry K.P., Tilson H.A. The role of 5HT1A receptors in the modulation of the acoustic startle reflex in rats. Psychopharmacology (Berl) 1989, 97:507-513.
36. Newman-Tancredi A., Martel J.C., Assie M.-B., Buritova J., Lauressergues E., Cosi C., Heusler P., Bruins S.L., Colpaert F.C., Vacher B., Cussac D. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br. J. Pharmacol. 2009, 156:338-353.
37. Ogren S.O., Eriksson T.M., Elvander-Tottie E., D'Addario C., Ekstrom J.C., Svenningsson P., Meister B., Kehr J., Stiedl O. The role of 5-HT(1A) receptors in learning and memory. Behav. Brain Res. 2008, 195:54-77.
38. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
39. Rigdon G.C., Weatherspoon J.K. 5-Hydroxytryptamine 1a receptor agonists block prepulse inhibition of acoustic startle reflex. J. Pharmacol. Exp. Ther. 1992, 263:486-493.
40. Robbins T.W. The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. Psychopharmacology (Berl) 2002, 163:362-380.
41. Rollema H., Lu Y., Schmidt A.W., Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol. 1997, 338:R3-R5.
42. Sambeth A., Blokland A., Harmer C.J., Kilkens T.O., Nathan P.J., Porter R.J., Schmitt J.A., Scholtissen B., Sobczak S., Young A.H., Riedel W.J. Sex differences in the effect of acute tryptophan depletion on declarative episodic memory: a pooled analysis of nine studies. Neurosci. Biobehav. Rev. 2007, 31:516-529.
43. Schechter L.E., Smith D.L., Rosenzweig-Lipson S., Sukoff S.J., Dawson L.A., Marquis K., Jones D., Piesla M., Andree T., Nawoschik S., Harder J.A., Womack M.D., Buccafusco J., Terry A.V., Hoebel B., Rada P., Kelly M., Abou-Gharbia M., Barrett J.E., Childers W. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther. 2005, 314:1274-1289.
44. Sipes T.A., Geyer M.A. 8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100, 135 and localization of site of action. Psychopharmacology (Berl) 1995, 117:41-48.
45. Stanhope K.J., McLenachan A.P., Dourish C.T. Dissociation between cognitive and motor/motivational deficits in the delayed matching to position test: effects of scopolamine, 8-OH-DPAT and EAA antagonists. Psychopharmacology (Berl) 1995, 122:268-280.
46. Tricklebank M.D., Forler C., Fozard J.R. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur. J. Pharmacol. 1984, 106:271-282.
47. Uchida S., Umeeda H., Kitamoto A., Masushige S., Kida S. Chronic reduction in dietary tryptophan leads to a selective impairment of contextual fear memory in mice. Brain Res. 2007, 1149:149-156.
48. van der Staay F.J. Spatial working memory and reference memory of Brown Norway and WAG rats in a holeboard discrimination task. Neurobiol. Learn. Mem. 1999, 71:113-125.
49. Zhong P., Yuen E.Y., Yan Z. Modulation of neuronal excitability by serotonin-NMDA interactions in prefrontal cortex. Mol. Cell. Neurosci. 2008, 38:290-299.